Literature DB >> 20840376

The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies.

A Bowyer1, S Kitchen, M Makris.   

Abstract

INTRODUCTION: The sensitivity of APTT reagents to deficiencies of factors VIII, IX, XI and XII varies because of their composition. The APTT is used as a screening test for these factors, and a deficiency should manifest with a prolongation to the APTT, which may trigger the need for specific factor assays to be performed.
METHODS: The suitability of APTT reagents to detect mild deficiencies can be assessed by the analysis of the APTT of plasma, which has an increasing concentration of the factor in question. The APTT responsiveness can be determined from the intersection of the curve and the upper limit of the APTT normal reference range for that APTT reagent. We assessed the APTT responsiveness (in U/dl) to factors VIII, IX and XI of four APTT reagents; Actin FS (Siemens), Synthasil (IL), STA-PTTA (Stago) and Dapttin (Technoclone).
RESULTS: Actin FS was the most sensitive reagent to mild reductions of factors VIII, IX and XI [Correction added on 26 October 2010, after first online publication: Synthasil was corrected to Actin FS]. STA-PTTA showed less sensitivity than Synthasil and Actin FS; Dapttin was insensitive to mild deficiencies of factors IX and XI and should not be used as a screening test.
CONCLUSION: Both Synthasil and Actin FS are acceptable reagents to screen for reduced factors VIII, IX and XI, and the number of mildly reduced factors not diagnosed will be limited.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840376     DOI: 10.1111/j.1751-553X.2010.01261.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  13 in total

1.  A sample-to-result system for blood coagulation tests on a microfluidic disk analyzer.

Authors:  Chia-Hui Lin; Cheng-Yuan Liu; Chih-Hsin Shih; Chien-Hsing Lu
Journal:  Biomicrofluidics       Date:  2014-08-22       Impact factor: 2.800

2.  What should be the laboratory approach against isolated prolongation of a activated partial thromboplastin time?

Authors:  Mesude Falay; Mehmet Senes; Dogan Yücel; Turan Turhan; Simten Dagdaş; Melike Pekin; Namik K Nazaroglu; Gülsüm Özet
Journal:  J Clin Lab Anal       Date:  2018-02-27       Impact factor: 2.352

Review 3.  Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management.

Authors:  Gary Benson; Günter Auerswald; Gerry Dolan; Anne Duffy; Cedric Hermans; Rolf Ljung; Massimo Morfini; Silva Zupančić Šalek
Journal:  Blood Transfus       Date:  2017-11-14       Impact factor: 3.443

4.  Factor XI as a target for preventing venous thromboembolism.

Authors:  David Gailani
Journal:  J Thromb Haemost       Date:  2022-01-12       Impact factor: 16.036

5.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

6.  Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.

Authors:  Annette E Bowyer; Joost J Van Veen; Anne C Goodeve; Steve Kitchen; Michael Makris
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

7.  Protective Effects of Total Flavones of Elaeagnus rhamnoides (L.) A. Nelson against Vascular Endothelial Injury in Blood Stasis Model Rats.

Authors:  Zhicheng Wei; Fang Zuo; Wenqian Wang; Li Wang; Dong Tong; Yong Zeng; Ping Wang; Xianli Meng; Yi Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2017-10-31       Impact factor: 2.629

8.  IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.

Authors:  Jason D Ferrone; Gourab Bhattacharjee; Alexey S Revenko; Thomas A Zanardi; Marshelle S Warren; Frederick J Derosier; Nicholas J Viney; Nguyen C Pham; Gwendolyn E Kaeser; Brenda F Baker; Eugene Schneider; Steven G Hughes; Brett P Monia; A Robert MacLeod
Journal:  Nucleic Acid Ther       Date:  2019-02-28       Impact factor: 5.486

9.  Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time in a patient with Hashimoto thyroiditis-associated thyroid cancer: A case report.

Authors:  Yuhong Zhong; Biyong Yan; Zhongqi Yu; Lin Wang
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

10.  Determination of APTT factor sensitivity--the misguiding guideline.

Authors:  A S Lawrie; S Kitchen; M Efthymiou; I J Mackie; S J Machin
Journal:  Int J Lab Hematol       Date:  2013-05-30       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.